SCHEMBL21553095

SCHEMBL21553095

CCOC(=O)CCc1cn(COCC[Si](C)(C)C)c(=O)c(N2CC3(COC3)C2)n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.37
DGAT1 O75907 4/20 0.35
DDX3X O00571 1/20 0.32
KLKB1 P03952 1/20 0.31
KDM4E B2RXH2 2/20 0.31
LMNA P02545 3/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
AKT1 P31749 1/20 0.31
SYK P43405 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CNR2 P34972 1/20 0.30
PDE3B Q13370 1/20 0.30
PDE3A Q14432 1/20 0.30
P2RY12 Q9H244 1/20 0.30
MBOAT4 Q96T53 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21564466 0.86 AKT1 (0.40) DGAT1LMNAALDH1A1AKT1GAA
SCHEMBL21552925 0.84 DGAT1 (0.38) DGAT1KDM4ELMNAALDH1A1
SCHEMBL21553058 0.84 SYK (0.33) PFKFB3DGAT1KLKB1SYK
SCHEMBL21553045 0.83 DGAT1 (0.35) DGAT1DDX3XKLKB1KDM4ELMNA
SCHEMBL21553014 0.82 SYK (0.32) SYK
SCHEMBL26031543 0.80 PFKFB3 (0.36) PFKFB3DGAT1KLKB1KDM4EMAPT
SCHEMBL21564597 0.79 PFKFB3 (0.37) PFKFB3DDX3XKDM4ELMNAALDH1A1
SCHEMBL21552888 0.78 DGAT1 (0.37) PFKFB3DGAT1KLKB1SYKCNR2
SCHEMBL21553086 0.77 GABRA2 (0.39) PFKFB3DDX3XKDM4ELMNAMAPT
SCHEMBL21552857 0.76 KLKB1 (0.34) PFKFB3KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A PFKFB3 4364/4885DGAT1 2741/4885DDX3X 865/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A PFKFB3 4364/4885DGAT1 2741/4885DDX3X 865/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A PFKFB3 4338/4885DGAT1 2605/4885DDX3X 1021/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A PFKFB3 4364/4885DGAT1 2741/4885DDX3X 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.